Clinical trials: Multiple Dose
Obesity, Type 2 Diabetes
A Three-part First-in-human Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GUB-UCN2 in Healthy Lean and Obese Participants and Participants With T2D
The trial will enroll healthy volunteers and individuals living with obesity, with and without Type 2 Diabetes. The study, with a treatment period of up to 16 weeks in selected cohorts, will investigate GUB-UCN2 as both a…
- Trial name
- NCT07702890
- Testing
- GUB-UCN2
- Where
- Germany
- Volunteers
- 188 people, healthy volunteers welcome
- Sponsor
- Gubra A/S
Neurological Disorder
Safety and Tolerability of Glyceryl Tribenzoate (GTB) Capsules in Healthy Subjects
This study is designed to assess the safety and PK/PD of GTB and Benzoic Acid (Benzoate) using a single ascending dose (SAD) study (under fasting conditions).
- Trial name
- NCT05938452
- Testing
- Glyceryl Tribenzoate
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Forest Hills Lab
Healthy Participants
Estimation of the Effect of Multiple Dose Ritlecitinib (PF-06651600) on the Pharmacokinetics of a Single Dose of Caffeine in Healthy Participants
This will be a Phase 1, 2 period, fixed sequence, multiple-dose, open-label study of the effect of ritlecitinib on caffeine PK in healthy participants.
- Trial name
- NCT04655040
- Testing
- Caffeine, Ritlecitinib
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Volunteer
Study to Assess the Adverse Events, Tolerability, and How Oral Doses of ABBV-932 Moves Through the Body in Healthy Adult Chinese Participants
This study will assess the adverse events, tolerability, and how oral doses of ABBV-932 moves through the body in healthy adult Chinese participants.
- Trial name
- NCT07024797
- Testing
- ABBV-932
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- AbbVie
Healthy Volunteer
A Multiple Ascending-Dose Study of RG7625 in Healthy Volunteers
This randomized, double-blind, placebo-controlled, ascending-dose, parallel-group study will evaluate the pharmacodynamic effects, pharmacokinetics, safety, and tolerability of one week of RG7625 dosing in healthy male and female…
- Trial name
- NCT02521610
- Testing
- RG7625
- Where
- Netherlands
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Healthy
Study in Healthy Subjects to Examine the Safety and Tolerability of ACT-1004-1239 Given as Multiple, Gradually Increasing Doses and to Examine the Effects of ACT-1004-1239 on the Body and the Way the Body Takes up, Distributes, and Gets Rid of ACT-1004-1239
Study in healthy subjects to examine the safety and tolerability of ACT-1004-1239 given as multiple, gradually increasing doses and to examine the effects of ACT-1004-1239 on the body and the way the body takes up, distributes…
- Trial name
- NCT04286750
- Testing
- ACT-1004-1239
- Where
- Portugal
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Healthy
A Phase I Study of Hetrombopag Olamine in Healthy Adult Volunteers
Hetrombopag Olamine made by Jiangsu Hengrui Medicine co Ltd. has shown an effect of increasing platelet count in animal and human.
- Trial name
- NCT01830660
- Testing
- Hetrombopag Olamine Tablets
- Where
- China
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Healthy Volunteers
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Bioavailability, and Food-effects of EA1080 in Healthy Caucasian and Japanese Male Participants
The primary purpose of the study is to evaluate the safety and tolerability of EA1080 following single and multiple ascending oral doses in healthy Caucasian and Japanese male participants.
- Trial name
- NCT04223960
- Testing
- EA1080
- Where
- United Kingdom
- Volunteers
- 184 people, healthy volunteers welcome
- Sponsor
- EA Pharma Co., Ltd.
Healthy
Bioequivalence of Pramipexole Extended Release (PPX ER) 1.5mg x 1 Tablet Once Daily (q.d.) vs. PPX ER 0.375mg x 4 Tablets Under Fasted and Fed Conditions in Japanese Healthy Volunteers
Bioequivalence between PPX ER 1.5 mg x 1 tablet q.d. and 0.375 mg PPX ER x 4 tablets q.d. under fasted and fed conditions Food effect of 1.5 mg ER x 1 tablet q.d.
- Trial name
- NCT01119443
- Testing
- PPX ER
- Where
- Japan
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
Effects of Repeated Doses of Foliglurax on Drug Metabolizing Enzymes in Healthy Subjects
The purpose of this study is to help determine which types of drugs that may interact with foliglurax
- Trial name
- NCT04275115
- Testing
- Drug Cocktail, Foliglurax, midazolam iv
- Where
- France
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
Influenza
Safety, Tolerability, and Immunogenicity of Different Combinations of Trivalent Influenza Vaccine Varying Influenza Antigen Dose, Adjuvant Dose, and Route of Administration in Healthy Elderly Individuals Ages 65 Years and Older
The study will evaluate the safety, tolerability and immunogenicity of different doses and types of Influenza Vaccine in healthy elderly subjects.
- Trial name
- NCT00848848
- Testing
- Trivalent Influenza Vaccine, Trivalent Influenza Vaccine + high A, Trivalent Influenza Vaccine + ¼ dose adjuvant
- Where
- Belgium
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Seqirus
Healthy
Study Evaluating Safety, Tolerability and Pharmacokinetics of EYP001a in Healthy Male Subjects
The farnesoid X receptor (FXR) regulates hepatitis B virus replication through the bile acids pathway. EYP001a is a selective, synthetic FXR agonist under development for the treatment of hepatitis B.
- Trial name
- NCT03110276
- Testing
- EYP001a
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Enyo Pharma
Healthy
A Study of MK-8507 and Islatravir (MK-8591) in Healthy Adult Participants (MK-8507-016)
The main goals of this study are to learn what happens to Islatravir or MK-8507 in a person's body over time. Researchers will compare Islatravir given alone to Islatravir given with MK-8507.
- Trial name
- NCT06619678
- Testing
- MK-8507, Islatravir
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Weight Management
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC35 Injection in Participants With Obesity or Overweight
This randomized, double-blind, placebo-controlled single ascending dose (SAD)/ multiple ascending dose (MAD) study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ASC35 injection
- Trial name
- NCT07842640
- Testing
- ASC35 Injection B, for subcutaneous use, Tirzepatide
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Ascletis Pharma (China) Co., Limited
Contraception
To Investigate the Pharmacological Effects, Drug Blood Levels and Safety of an Intrauterine System Releasing the Study Drug BAY1007626 in Comparison to Mirena and Jaydess in Healthy Young Women Treated for 90 Days to Determine the Drug Dose for Further Development
Investigation of pharmacological effects, drug blood levels and safety of an intrauterine system releasing the study drug BAY1007626 in comparison to Mirena and Jaydess in healthy young women treated for 90 days to determine the…
- Trial name
- NCT02490774
- Testing
- BAY1007626, Jaydess, Mirena
- Where
- 7 sites in Germany, Netherlands and 1 more
- Volunteers
- 174 people, healthy volunteers welcome
- Sponsor
- Bayer
First in Man Study to Evaluate Initial Safety
Safety, Tolerability and Pharmacokinetics of RNV-166 in Healthy Male Volunteers
This Phase 1 first-in-human clinical study evaluated the safety, tolerability, and pharmacokinetics of RNV-166 following single ascending dose (SAD) and multiple ascending dose (MAD) administration in healthy participants.
- Trial name
- NCT07809360
- Testing
- RNV-166_200 mg
- Where
- Bangladesh
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- InVitro Research Solutions Private Limited
Irritable Bowel Syndrome
Phase I Clinical Trial of DA-6886 in Healthy Male Subjects
DA-6886_IBS_I is a phase I, dose block-randomized, double-blind, placebo-controlled, single/multiple dosing, dose escalation clinical trial with open-labelled food effect study of single dose to investigate the safety…
- Trial name
- NCT01633723
- Testing
- DA-6886
- Where
- South Korea
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Dong-A ST Co., Ltd.
Anthrax
Trial of rPA-102 Vaccine in Healthy Adult Volunteers
The purpose of this study is to assess the safety and immunogenicity of rPA102 vaccine given intramuscularly at 0 and 4 weeks over 2 dose ranges and 4 adjuvant levels.
- Trial name
- NCT00100724
- Testing
- rPA102
- Where
- 12 sites in United States
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- VaxGen
Healthy
Single and Multiple Ascending Dose Study for NKTR-118 and Cross-over Study to Investigate the Effect of Food for NKTR-118 in Japanese Healthy Subjects
The purpose of this study is to evaluate the safety and tolerability of NKTR-118 with healthy subjects.
- Trial name
- Japan SMAD (NCT01318655)
- Testing
- NKTR-118
- Where
- Japan
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Rivipansel With rHuPH20 in Healthy Subjects
This is a 2 part study designed to provide an initial assessment on the safety, tolerability, and PK of rivipansel, following single ascending (Part 1) and multiple ascending dosing (Part 2) given subcutaneously with rHuPH20, in…
- Trial name
- NCT02217917
- Testing
- Rivipansel
- Where
- Belgium
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- GlycoMimetics Incorporated